A pyrosequencing assay for the quantitative methylation analysis of the PCDHB gene cluster, the major factor in neuroblastoma methylator phenotype

Laboratory Investigation

Volumn 92, Issue 3, 2012, Pages 458-465

  Banelli, Barbara ^a   Brigati, Claudio ^a   Di Vinci, Angela ^a   Casciano, Ida ^a   Forlani, Alessandra ^a   Borz, Luana ^a   Allemanni, Giorgio ^a   Romani, Massimo ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

DNA methylation; epigenetics; methylator phenotype; neuroblastoma; protocadherin B; pyrosequencing

Indexed keywords

BIOLOGICAL MARKER; CADHERIN; PROTOCADHERIN B; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; CLINICAL ARTICLE; COMPUTER PROGRAM; CPG ISLAND; CPG ISLAND METHYLATOR PHENOTYPE; DNA METHYLATION; EPIGENETICS; GENE AMPLIFICATION; GENE CLUSTER; GENE LOCUS; GENETIC VARIABILITY; HUMAN; NEUROBLASTOMA; PATIENT IDENTIFICATION; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; PYROSEQUENCING; QUANTITATIVE ASSAY; REPRODUCIBILITY; RISK ASSESSMENT; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY;

CADHERINS; CHILD; CHILD, PRESCHOOL; CPG ISLANDS; DNA METHYLATION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MULTIGENE FAMILY; NEUROBLASTOMA; PHENOTYPE; RISK ASSESSMENT; SEQUENCE ANALYSIS, DNA;

EID: 84857740783     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2011.169     Document Type: Article

References (30)

1. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006;7:21-33. (Pubitemid 41828945)
2. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004;4:143-153. (Pubitemid 38198742)
3. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-428. (Pubitemid 34587077)
4. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999;96: 8681-8686. (Pubitemid 29354851)
5. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004;4:988-993.
6. Teodoridis JM, Hardie C, Brown R. CpG island methylator phenotype (CIMP) in cancer: causes and implications. Cancer Lett 2008;268: 177-186.
7. Abe M, Ohira M, Kaneda A, et al. CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res 2005;65:828-834. (Pubitemid 40216441)
8. Abe M, Watanabe N, McDonell N, et al. Identification of genes targeted by CpG island methylator phenotype in neuroblastomas, and their possible integrative involvement in poor prognosis. Oncology 2008;74:50-60. (Pubitemid 351915010)
9. Abe M, Westermann F, Nakagawara A, et al. Marked and independent prognostic significance of the CpG island methylator phenotype in neuroblastomas. Cancer Lett 2007;247:253-258. (Pubitemid 46240612)
10. Ushijima T, Okochi-Takada E. Aberrant methylations in cancer cells: where do they come from? Cancer Sci 2005;96:206-211. (Pubitemid 40767056)
11. Dallosso AR, Hancock AL, Szemes M, et al. Frequent long-range epigenetic silencing of protocadherin gene clusters on chromosome 5q31 in Wilms0 tumor. PLoS Genet 2009;5:e1000745.
12. Novak P, Jensen T, Oshiro MM, et al. Agglomerative epigenetic aberrations are a common event in human breast cancer. Cancer Res 2008;68:8616-8625.
13. Alaminos M, Davalos V, Cheung NK, et al. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J Natl Cancer Inst 2004;96:1208-1219. (Pubitemid 39232712)
14. Banelli B, Bonassi S, Casciano I, et al. Outcome prediction and risk assessment by quantitative pyrosequencing methylation analysis of the SFN gene in advanced stage, high-risk, neuroblastic tumor patients. Int J Cancer 2010;126:656-668.
15. Banelli B, Gelvi I, Di Vinci A, et al. Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors. Oncogene 2005;24:5619-5628. (Pubitemid 43119355)
16. Yagyu S, Gotoh T, Iehara T, et al. Circulating methylated-DCR2 gene in serum as an indicator of prognosis and therapeutic efficacy in patients with MYCN nonamplified neuroblastoma. Clin Cancer Res 2008;14:7011-7019.
17. Banelli B, Di Vinci A, Gelvi I, et al. DNA methylation in neuroblastic tumors. Cancer Lett 2005;228:37-41. (Pubitemid 41188422)
18. Kagan J, Srivastava S, Barker PE, et al. Towards clinical application of methylated DNA sequences as cancer biomarkers: A Joint NCI's EDRN and NIST Workshop on Standards, Methods, Assays, Reagents and Tools. Cancer Res 2007;67:4545-4549. (Pubitemid 46910155)
19. Duffy MJ, Napieralski R, Martens JW, et al. Methylated genes as new cancer biomarkers. Eur J Cancer 2009;45:335-346.
20. Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009;27:289-297.
21. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-1477. (Pubitemid 23228250)
22. Tonini GP. Neuroblastoma: a multiple biological disease. Eur J Cancer 1993;29A:802-804. (Pubitemid 23083604)
23. Tost J, Gut IG. DNA methylation analysis by pyrosequencing. Nat Protoc 2007;2:2265-2275. (Pubitemid 351575045)
24. Shen L, Guo Y, Chen X, et al. Optimizing annealing temperature overcomes bias in bisulfite PCR methylation analysis. Biotechniques 2007;42:48, 50, 52 passim.
25. Dupont JM, Tost J, Jammes H, et al. De novo quantitative bisulfite sequencing using the pyrosequencing technology. Anal Biochem 2004;333:119-127. (Pubitemid 39209229)
26. Oki Y, Aoki E, Issa JP. Decitabine-bedside to bench. Crit Rev Oncol Hematol 2007;61:140-152. (Pubitemid 46073782)
27. Nakagawachi T, Soejima H, Urano T, et al. Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer. Oncogene 2003;22:8835-8844. (Pubitemid 38021499)
28. Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a highthroughput assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
29. Paliwal A, Vaissiere T, Herceg Z. Quantitative detection of DNA methylation states in minute amounts of DNA from body fluids. Methods 2010;52:242-247.
30. Clark SJ. Action at a distance: epigenetic silencing of large chromosomal regions in carcinogenesis. Hum Mol Genet 2007;16 (Spec No 1):R88-R95. (Pubitemid 47241847)